Endocrine Abstracts

Objective: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium – glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes(T2D) at high CV risk. SGLT2-i should be considered as a valuable therapy in T2D with established atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF). We analyzed the effects of cardiovascular function of SGLT 2 inhibitors in T2D with ASCVD or HF compared with dipeptidyl peptidase-4(DPP-4) inhibitors.

Methods: This is a retrospective, observational study, data from 89 patients with established ASCVD or HF 6 months of the SGLT-2 inhibitors and DPP-4 inhibitors therapy were analyzed, visited medical center from January 2018 to June 2018. We had divided into two groups: one group was SGLT-2 inhibitors and the other was DPP-4 inhibitors and check echocardiography and pro BNP.

Results: A total of 89 patients with T2D were identified as group of SGLT2 inhibitor (n=41) or a DPP-4 inhibitor (n=48). In SGLT2 inhibitors,mean baseline age was 59 years, duration of diabetes 10 years, HbA1C 7.8%, eGFR 81 ml/min per 1.73 m² and body mass index (BMI) 26 kg/m². In DPP4 inhibitors,mean baseline age was 65 years, duration of diabetes 13 years, HbA1C 7.6%, eGFR 67 ml/min per 1.73 m² and body mass index (BMI) 26 kg/m². The mean follow-up time was 2 years, with a total of 89 patient-years. SGLT2 inhibitors had improvement of left ventricular ejection fraction (+2% vs −2.7%), E/E’ (3/40% vs 5/21%)and pro BNP (−374 pg/ml vs +735 pg/ml) compared with DPP-4 inhibitors.

Conclusion: SGLT-2 inhibitors improved LV systol, diastolic function and proBNP compared with DPP-4 inhibitors in type 2 diabetes with coronary artery disease.